Once enacted, the proposal will give any adult in the state, aged 21 and over, the legal right to possess, use, cultivate and share psilocybin, ibogaine, mescaline (not derived from peyote), DMT, and psilocyn without fear of arrest.
Based on these findings, the researchers theorize that more restrictive frameworks for cannabis use may not be effective at preventing use during times of great stress.
The delta-8 market urgently needs more oversight and higher safety standards, according to a new viewpoint letter.
A new study has found that a single microdose of LSD can increase brain activity related to its reward system.
The largest study to date testing the ability of the psychedelic compound psilocybin to treat a psychiatric disorder has shown that the mushroom-derived drug, delivered in combination with integrative psychotherapy sessions, significantly reduced participants’ depression as compared to a placebo after three weeks.
If you need to quickly assess whether a patient might have cannabis use disorder, ask them how often they’ve used cannabis in the past year. At least, that is the suggestion put forward in new research published this week.
Writing in the Conversation, Benjamin Land, a research associate professor of pharmacology at the University of Washington, explains how cannabis could be used as an opioid substitute.
The certificate was awarded on October 20 to Viridis Laboratories, a cannabis lab in Michigan.
The state’s Office of Cannabis Management has removed the pass/fail limits associated with the total yeast and mold counts for cannabis flower and pre-rolls.
Chris Hudalla, president and chief scientific officer at ProVerde Laboratories, explores the legality and implications of novel synthetic cannabinoids.